OAM
ANIK icon

Oberweis Asset Management’s Anika Therapeutics ANIK Stock Holding History

Oberweis Asset Management’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-15,450
Closed -$566K – 128
2014
Q3 		$566K Sell
15,450
-12,150
-44% -$525K 0.16% 77
2014
Q2 		$1.28M Buy
27,600
+21,100
+325% +$938K 0.32% 70
2014
Q1 		$267K Buy
+6,500
New +$242K 0.06% 129

Other funds holding ANIK

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
TSW
Thompson Siegel & Walmsley Richmond, Virginia $5.57B AUM 9.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.58B AUM 51% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
GAM
Gotham Asset Management New York $43B AUM 34.97% 1-Year Est. Return

Oberweis Asset Management's ANIK Position: Q4 2014 in Review

Oberweis Asset Management sold out of Anika Therapeutics (ANIK) in Q4 2014, closing a stake of 15,450 shares — an estimated $566K sold.

Oberweis Asset Management first reported a position in ANIK in Q1 2014 and held it in 3 quarters. The position peaked at $1.28M in Q2 2014. 160 funds tracked by Wall St. Rank hold ANIK as of Q4 2014.

  • Oberweis Asset Management reported no remaining Anika Therapeutics position as of Q4 2014 after selling out during the quarter.
  • Oberweis Asset Management sold 15,450 Anika Therapeutics shares in Q4 2014, an estimated $566K.
  • Oberweis Asset Management first reported a position in Anika Therapeutics in Q1 2014 and held it in 3 quarters.
  • Oberweis Asset Management's Anika Therapeutics position peaked at $1.28M in Q2 2014.
  • 160 funds tracked by Wall St. Rank held Anika Therapeutics as of Q4 2014.

Based on Oberweis Asset Management's 13F filing for Q4 2014, filed 13 Feb 2015.